Skip To Main Content
Lirit Fuksman on Muck Rack

Lirit Fuksman

As seen in: The BMJ, JAMA Network
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lirit

Contact Lirit, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Enfortumab Vedotin−Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma

|
By Eudora Lee, Ralina Karagenova, Charles Lu, Parisa Farokh, Marjan Azin, Federico Repetto, Soma Jobbagy, Rosalynn M Nazarian, Kerry L. Reynolds, Shadmehr Demehri, Philip J. Saylor, Lirit Fuksman, Yevgeniy R. Semenov
| JAMA Network Verified
Enfortumab Vedotin−Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma Key Points Question Among patients with advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV), is development of EV-induced cutaneous adverse events (cAEs) associated with improved survival, and how does this association compare with cutaneous immune-related adverse events (cirAEs)?
Open in Who Shared Issue with article?

Evaluating the safety of Janus kinase inhibitors in the management of severe immune-related adverse events

|
By Eudora Lee, Ralina Karagenova, Lirit Fuksman
| The BMJ Verified
Background Immune checkpoint inhibitors (ICIs) have transformed the treatment of cancer.
Open in Who Shared Issue with article?
See all 2 articles